EYPT Overview
Upcoming Projects (EYPT)
Executed Projects (EYPT)
-
Discussing the potential of Roche's Susvimo, a surgical ocular implant designed to slowly release ranibizumab for the treatment of Wet-AMD.
Tickers: RHHBY, REGN, OCUL, EYPT
Executed On: Jul 18, 2024 at 03:00 PM EDT -
A Third View: Wet AMD Treatment Landscape: In-Depth Analysis of EyePoint's EYP-1901 and 4D Molecular's 4D-150 from their recent Clinical Trials
Tickers: FDMT, EYPT
Executed On: Mar 12, 2024 at 04:00 PM EDT -
A Second View: Wet AMD Treatment Landscape: In-Depth Analysis of EyePoint's EYP-1901 and 4D Molecular's 4D-150 from their recent Clinical Trials
Tickers: FDMT, EYPT
Executed On: Feb 29, 2024 at 09:00 AM EST -
Wet AMD Treatment Landscape: In-Depth Analysis of EyePoint's EYP-1901 and 4D Molecular's 4D-150 from their recent Clinical Trials
Tickers: EYPT, FDMT
Executed On: Feb 14, 2024 at 04:00 PM EST -
A Second Opinion: Reviewing the top-line results of EyePoint's Phase II DAVIO 2 trial of EYP-1901 for wet-AMD
Ticker: EYPT
Executed On: Dec 15, 2023 at 09:00 AM EST -
Reviewing the top-line results of EyePoint's Phase II DAVIO 2 trial of EYP-1901 for wet-AMD
Ticker: EYPT
Executed On: Dec 07, 2023 at 03:00 PM EST -
A Second View: Comparing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, FDMT
Executed On: Feb 15, 2023 at 06:30 PM EST -
Comparing EyePoint's EYP-1901 and 4D Molecular Therapeutics' gene therapy, 4D-150 for the treatment of wet-AMD
Tickers: EYPT, REGN, FDMT
Executed On: Feb 06, 2023 at 05:00 PM EST -
Digging into EyePoint Pharma's recent phase 1 data on its anti-VEGF candidate, EYP-1901 in macular edema and wet-AMD
Tickers: EYPT, REGN
Executed On: Sep 07, 2022 at 05:00 PM EDT
Upcoming & Overdue Catalysts (EYPT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (EYPT)
-
EyePoint and ImprimisRx expand commercial alliance for Dexycu
Ticker: EYPT
Announcement Date: Dec 07, 2021
